Ab Science SA (ABS.PA)

ABS.PA on Paris Stock Exchange

10.89EUR
11:35am EST
Price Change (% chg)

€-0.43 (-3.80%)
Prev Close
€11.32
Open
€11.40
Day's High
€11.45
Day's Low
€10.81
Volume
116,433
Avg. Vol
142,079
52-wk High
€16.83
52-wk Low
€7.16

ABS.PA

Chart for ABS.PA

About

AB Science SA, also known as AB Science, is a France-based pharmaceutical company specialized in the research, discovery, development and marketing of protein kinase inhibitors (PKIs). It is engaged in targeted therapies through tyrosine kinase inhibitors for treating diseases with high medical factor in the field of cancer,... (more)

Overall

Beta: 0.98
Market Cap (Mil.): €372.71
Shares Outstanding (Mil.): 32.93
Dividend: --
Yield (%): --

Financials

  ABS.PA Industry Sector
P/E (TTM): -- 38.28 39.18
EPS (TTM): -0.47 -- --
ROI: -61.99 17.89 17.24
ROE: -- 18.63 18.11
Search Stocks

BRIEF-AB Science says data and safety monitoring board recommends continuation of phase 2 study with Masitinib in advanced Hepatocellular Carcinoma

* The data and safety monitoring board recommends the continuation of the phase 2 study with Masitinib in advanced hepatocellular carcinoma Source text for Eikon: Further company coverage: (Gdynia Newsroom: +48 58 698 39 20)

12 Nov 2014

BRIEF-AB Science announces positive preclinical results of studies on masitinib

* Announces positive preclinical results of studies on masitinib

30 Oct 2014

BRIEF-AB Science Q3 revenue 532,000 euros versus 442,000 euros last year

* Q3 revenue 532,000 euros versus 442,000 euros last year Source text for Eikon: Further company coverage: (Gdynia Newsroom: +48 58 698 39 20)

15 Oct 2014

BRIEF-Ab Science says DSMB recommends continuation of its phase 3 study of Masitinib in mastocytosis

* Says external Data and Safety Monitoring Board (DSMB) has recommended continuation of its phase 3 study of Masitinib in mastocytosis

30 Sep 2014

BRIEF-AB Science total net loss up at 7.2 mln euros as at June 30

* On Friday AB Science reported total net loss of 7.2 million euros as at June 30 versus net loss of 6.3 million euros as at June 30, 2013

01 Sep 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks